In the immuno-oncology field, scientists discover, test, and validate novel immunotherapeutic agents that leverage the human immune system to fight cancer, such as checkpoint inhibitors, vaccine-based ...

This article is based on a poster originally authored by Yongyang Huang, Ning Guo, Mackenzie Pierce, Leo Chan, Bo Lin and Yi Yang, which was presented at ELRIG Drug Discovery 2024 in affiliation with ...

CellVoyant, an AI-first biotech based in Bristol UK,  today launches FateView™, the first online predictive cell analytics platform designed to help cell-based therapeutic drug developers reduce costs ...

Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...

In this video, Analytik Jena demonstrates how its advanced liquid handling technology—specifically the CyBio Felix platform—enhances and simplifies cell-based assay workflows. In collaboration with ...

In the ever-evolving landscape of biomedical research, the need for reliable, consistent, and ready-to-use cell models has never been more critical. ATCC, a leading provider of biological materials, ...

Partillion Bioscience provides Nanovials, engineered microparticles that serve as suspendable reaction compartments for individual cells. Nanovials come in 35 µm or 50 µm diameters, and different ...

A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.

Cellular immunogenicity and immunotoxicity assays help scientists design, validate, and translate therapeutic research into treatments that weaponize the immune response against cancer.